aion therapeutic news

05/18: AFRIAG GLOBAL : Combined Apollon and Aion Formulations Kill Breast Cancer Cells.. AQ. Aion Therapeutic, formerly known as Osoyoos Cannabis Inc., has a joint-venture agreement with a private, vertically-integrated licensed producer under the Cannabis Act (Canada) to offer contract tolling extraction services to third-party businesses.Additionally, the Company recently acquired PCAI Pharma and its wholly-owned subsidiary AI Pharmaceuticals Jamaica Limited – a … More information on the site! Aion Therapeutic’s Proprietary Mushroom Preparations Shown Effective in Killing Breast Cancer Cells. In brief Deep dive Research Latest news Insight Interviews. News provided by. Read the PBIC Announces Investment in Aion Therapeutic Inc. - Investing News Network and find out a lot of new information with us. April 21, 2021. in Cannabis Science & Technology News. Upcoming Events for AION. PLANT-BASED INVESTMENT CORP. TORONTO , March 11, 2021 /CNW/ - Aion Therapeutic Inc. (CSE: AION) (" Aion Therapeutic " or the " Company ") announced today that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms.The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical … Detroit, Michigan--(Newsfile Corp. - June 2, 2021) - Aion Therapeutic Inc (CSE: AION) will be presenting at the Benzinga Cannabis Capital Conference taking place on June 3-4, 2021, with CEO J Graham Simmonds presenting at 4:55pm Eastern, Thursday June 3rd 2021. 06/02: Aion Therapeutic Inc to Present at Benzinga Virtual Cannabis Capital Conferen.. NE. The Medical Director of the Aion International Center for Psychedelic Psychiatry is Winston De La Haye, M.D., M.P.H, D.M., Aion Therapeutic Inc to Present at Benzinga Virtual Cannabis Capital Conference Investing News Network - June 2nd, 2021 Aion Therapeutic Inc will be … Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. TORONTO, ON / ACCESSWIRE / June 11, 2021 / Plant-Based Investment Corp. (the 'Company') (CSE:PBIC) announces the filing of an early warning report in connection with the acquisition of 9,714,286 units (each, a 'Unit') of Aion Therapeutic Inc. ('Aion Therapeutic') (CSE: AION) through a non-brokered private placement (the 'Offering') at a price of $0.0875 per Unit for a total subscription … Aion Therapeutics Inc: Aion Therapeutics closes $1.48-million financing: Fr: Plant-Based Investment Corp. View all news. Following Aion’s initial announcement on April 23, 2021 revealing the effectiveness of its mushroom formulation in killing breast cancer cells, the Company saw its stock performance spike. Neuroscientist, Healthcare Technology Entrepreneur to Lead Aion Through Important Next PhaseToronto, Ontario--(Newsfile Corp. - October 21, 2020) - Aion Therapeutic Inc. (CSE: AION) ('Aion Therapeutic' or the 'Company') is pleased to announce that the Company has named James W.G. Get the latest stock price for Aion Therapeutic Inc. (AION:APH), plus the latest news, recent trades, charting, insider activity, and analyst ratings. Aion Therapeutic Inc (CSE:AION) CEO, Dr Stephen Barnhill presents at Proactive's One2One virtual investor forum. Autophagy is a lysosome degradation pathway that is … The stock options were granted on February 2, 2021 in accordance … Real-time discussion about Aion Therapeutic Inc. (AION.CN) on CEO.CA, an investment chat community for Canada's small cap markets Aion Therapeutic Inc , Lobe Sciences Ltd (OTCMKTS: (GTSIF) and Silo Pharma Inc (OTCMKTS:SILO) are presenting at Proactive’s next virtual showcase event on February 23. The proceeds of the Offering will be used for … Formerly known Osoyoos Cannabis Inc., Aion Therapeutic Inc. (CNSX:AION) researches, grows, and markets medical cannabis in Canada. Home of the insider insights newsletter and the Canadian Insider Club which offers alerts and premium research. Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry in Jamaica; Hires Leading Psychiatrist as Medical Director 2021-02-23 10:58 AM EST; Aion Therapeutic Announces Closing of Non-Brokered Private Placement 2021-02-22 6:30 PM EST; Aion Therapeutic Grants Stock Options; Announces Management Change This news release is being issued in accordance with National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues in … AION’s stock soared on the news but has since consolidated in the $.11-$.12 range: AION is still in the early discovery stage of drug development and will need to conduct several animal studies before gaining the confidence to enter Phase 1 human clinical trials and commercialize a FDA approved drug. Moreover, the news seems to have generated positive investor sentiment with many investors opting to hold their positions in anticipation of Aion’s success. Detroit, Michigan--(Newsfile Corp. - June 2, 2021) - Aion Therapeutic Inc (CSE: AION) will be presenting at the Benzinga Cannabis Capital Conference taking place on June 3-4, 2021, with CEO J Graham Simmonds presenting at 4:55pm Eastern, Thursday June 3rd 2021. Aion Therapeutic Announces Closing of Non-Brokered Private Placement. Toronto, Ontario--(Newsfile Corp. - June 11, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 16,994,475 units (each, a "Unit") at a price of $0.0875 per Unit for gross proceeds of $1,487,016.56 (the "Offering"). Toronto, Ontario--(Newsfile Corp. - June 11, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a … CBD NEWS INSIDER No Result . News provided by. As of 28/05/21, shares in Aion Therapeutic Inc are trading at C$0.085, giving the company a market capitalisation of £6.55m. Aion Therapeutic Inc presents at Proactive's One2One virtual investor forum . The only place for free North American stock rankings incorporating insider commitment. Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the "Aion Mushroom Preparations" or "Preparations") showed high efficacy in killing HER2+ breast cancer cells, ER+/PR+ breast cancer cells, and triple-negative breast cancer cells by direct … The company was founded on January 13, … Aion Therapeutic Inc said a ... New Deli, with its retail outlet located in Venice Beach, California, is a sustainable and plant-based neighborhood bodega offering retail goods that range from household supplies and personal hygiene products to frozen foods, pantry staples, snacks, beer, and wine. Plant-Based increases Aion shareholding to 16.96%. Aion Therapeutic Files 4 New Patent Applications (Including for the Treatment of Human Cancers) Post published: March 11, 2021; Post category: Press Release; Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry in Jamaica; Hires Leading Psychiatrist as Medical Director . Aion Therapeutic Inc. is an early-stage cannabinoid extraction company based in Oliver, BC. Aion has applied for a standard processing license under the Cannabis Act for its 10,410 ft2 facility and that application is currently in the review stage. Aion Therapeutics Inc. specializes in the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceutical compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations and other medicinal plants through its wholly owned subsidiary, AI … Toronto, Ontario--(Newsfile Corp. - February 23, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today the opening of the Aion International Center for Psychedelic Psychiatry in Jamaica. Share this article-Las formulaciones combinadas de Apollon y Aion … Aion Therapeutic Inc has revealed that its proprietary and patented combinatorial mushroom preparations, AION F7 and AION F8, showed high efficacy in killing multiple types of breast cancer cells. We invite our shareholders and all interested parties to join us for a full day of networking, dealmaking and discovery. Plant-Based Investment Corp. The HTI therapeutic vaccine is designed to stimulate T-cell responses to these regions, or epitopes. Home Cannabis Science & Technology News. Company profile page for Aion Therapeutic Inc including stock price, company news, press releases, executives, board members, and contact information Aion has applied for a standard processing license under the Cannabis Act for its 10,410 ft2 facility and that application is currently in the review stage. 0. The epitopes were selected after studying immune responses in around 1000 people with HIV. Aion Therapeutic Inc Com stock and Drug Manufacturers - Major market discussion, news, and analysis from Canada's largest community of active investors. Management Appointment In October, the company confirmed the … Barron's also provides information on historical stock ratings, target … Toronto, Ontario--(Newsfile Corp. - February 22, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a … Latest News for AION. TORONTO, March 11, 2021 /PRNewswire/ - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms.The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical … Aion Therapeutic, Inc. intends to engage in the business of processing raw cannabis to produce concentrated extracts which may be consumed directly or infused into a variety of recreational or medicinal products. Toronto, Ontario--(Newsfile Corp. - October 21, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that the Company has named James W.G. TORONTO, ON / ACCESSWIRE / June 11, 2021 / Plant-Based Investment Corp. (the "Company") (CSE:PBIC) announces the filing of an early warning report in connection with the acquisition of 9,714,286 units (each, a "Unit") of Aion Therapeutic Inc. ("Aion Therapeutic") (CSE: AION) through a non-brokered private placement (the "Offering") at a price of $0.0875 per Unit for a total subscription … About Aion Therapeutic Inc. Aion Therapeutic Inc. is an international pharmaceutical, nutraceutical and cosmeceuticals business headquartered … Toronto, Ontario--(Newsfile Corp. - December 23, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 15,384,615 units ("Units") at a price of $0.065 per Unit for gross proceeds of $1,000,000 (the "Offering"). Aion Therapeutic Inc (CSE:AION) (OTCMKTS:ANTCF) has raised C$1,487,016.56 gross from a private placing, which will be used for general working capital purposes. Aion Therapeutic Inc announced Thursday that it has filed four new patent applications related to preparations of medicinal and psychedelic mushrooms.In a statement, the company said the patent applications include the use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical cannabis and medicinal mushroom preparations for the …